CG Oncology (CGON) Free Cash Flow (2023 - 2026)
CG Oncology's (CGON) quarterly Free Cash Flow came in at -$57.2 million in Q1 2026, down 95.28% YoY from -$1.2 billion in Q1 2025, and down 57.99% on a QoQ basis from -$36.2 million in Q4 2025.
CG Oncology (CGON) Free Cash Flow (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Free Cash Flow data on file, last reported at -$57.2 million in Q1 2026.
- Quarterly Free Cash Flow fell 95.28% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.3 million (down 95.03% YoY) and the FY2025 annual result came in at -$132.4 million, down 67.75% from the prior year.
- Free Cash Flow slipped to -$57.2 million in Q1 2026, from -$36.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$8.0 million in Q1 2023 to a low of -$57.2 million in Q1 2026.
- A 4-year average of -$24.2 million and a median of -$20.9 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 225.87% — and 2025, when it decreased 12.56%.
- Tracing CGON's Free Cash Flow over 4 years: stood at -$14.6 million in 2023, then slumped by 42.51% to -$20.9 million in 2024, then slumped by 73.48% to -$36.2 million in 2025, then slumped by 57.99% to -$57.2 million in 2026.
- The last three Free Cash Flow figures came in at -$57.2 million (Q1 2026), -$36.2 million (Q4 2025), and -$39.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | -46.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.93 Mn |
| Jun 30, 2026 | -46.93 Mn |
| Mar 31, 2026 | -57.20 Mn |
| Mar 31, 2026 | -57.20 Mn |
| Dec 31, 2025 | -36.21 Mn |
| Dec 31, 2025 | -36.21 Mn |
| Sep 30, 2025 | -38.96 Mn |
| Sep 30, 2025 | -38.96 Mn |
| Jun 30, 2025 | -27.97 Mn |
| Jun 30, 2025 | -27.97 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Mar 31, 2024 | -26.02 Mn |
| Mar 31, 2024 | -26.02 Mn |